Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1

Starr, Stuart E.; Fletcher, Courtney V.; Spector, Stephen A.; Yong, Florence H.; Fenton, Terence; Brundage, Richard C.; Manion, Douglas; Ruiz, Nancy M.; Gersten, Merril; Becker, Mark; McNamara, James; Purdue, Lynette; Siminski, Suzanne; Graham, Bobbie; Kornhauser, David M.; Fiske, William; Vincent, Carol; Lischner, Harold W.; Dankner, Wayne M.; Flynn, Patricia M.
December 1999
New England Journal of Medicine;12/16/99, Vol. 341 Issue 25, p1874
Academic Journal
Background: Consistent long-term viral suppression has been difficult to achieve in children with human immunodeficiency virus type 1 (HIV-1) infection. We tested the safety and antiviral efficacy of a novel combination consisting of efavirenz, nelfinavir, and one or more nucleoside reverse-transcriptase inhibitors in 57 children previously treated with only nucleoside reverse-transcriptase inhibitors. Methods: The children were monitored for 48 weeks after the initiation of therapy. We assessed plasma concentrations of efavirenz and nelfinavir, plasma HIV-1 RNA levels, and lymphocyte subpopulations. Results: At base line, the 57 HIV-1–infected children (age range, 3.8 to 16.8 years) had a median of 699 CD4 cells per cubic millimeter and 10,000 copies of HIV-1 RNA per milliliter of plasma. The most common treatment-related effects of at least moderate severity were rash (in 30 percent of children), diarrhea (in 18 percent), neutropenia (in 12 percent), and biochemical abnormalities (in 12 percent). Serious side effects were uncommon. The mean values for the area under the curve for efavirenz and nelfinavir corresponded to expected values. In an intention-to-treat analysis, 76 percent of children had plasma HIV-1 RNA levels of less than 400 copies per milliliter after 48 weeks of therapy and 63 percent had levels of less than 50 copies per milliliter. A high plasma HIV-1 RNA level at base line significantly decreased the likelihood that plasma levels of HIV-1 RNA would become undetectable during treatment. Conclusions: In HIV-1–infected children who were previously treated with nucleoside reverse-transcriptase inhibitors, the combination of efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors was generally well tolerated and had a potent and sustained antiviral effect. (N Engl J Med 1999;341:1874-81.)


Related Articles

  • MIGENIX INITIATES ENROLLMENT IN PHASE IIB HEPATITIS TRIAL.  // Worldwide Biotech;Jan2006, Vol. 18 Issue 1, p1 

    The article reports on the launch of a Phase IIb combination therapy clinical trial of celgosivir by Migenix Inc. which aimed to develop a treatment of chronic hepatitis C virus as of January 2006. Migenix CEO Jim DeMesa offered a statement on the drug. The study is an evaluation of the drug in...

  • Maraviroc. Girotto, Jennifer E. // Formulary;Oct2007, Vol. 42 Issue 10, p601 

    Maraviroc is the first CCR5 antagonist approved for the treatment of HIV-1 infection. The use of maraviroc is associated with significant decreases in HIV viral load and increases in CD4 counts in antiretroviral treatment-experienced patients with CCR5-tropic virus when used as an add-on to...

  • A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Kolb, E.A.; Steinherz, P.G. // Leukemia (08876924);Oct2003, Vol. 17 Issue 10, p1967 

    We report the results of a phase 2 nonrandomized single-arm trial of a combination therapy for relapsed or refractory leukemia. From January 1999 to June 2002, 28 patients with multiple relapsed or refractory acute leukemia received a combination of topotecan, vinorelbine, thiotepa,...

  • Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Mauskopf, J.A.; Cates, S.C.; Griffin, A.D.; Neighbors, D.M.; Lamb, S.C.; Rutherford, C. // PharmacoEconomics;2000, Vol. 17 Issue 6, p611 

    Objective: To use data from a clinical trial of zanamivir, a new antiviral drug, to estimate the costs and effectiveness of alternative treatment strategies for a high-risk population in Australia visiting a physician for treatment of influenza or influenza-like illness within 36...

  • Trimeris/Roche Report Good Test Results From T-20 HIV Drug.  // Biotech Business;Dec99, Vol. 12 Issue 12, p2 

    Reports that Trimeris Inc. and Hoffman-La Roche Inc. have announced 16-week results from an evaluation of T-20 HIV drug in an on-going clinical trial in December 1999.

  • HIVers needed for flu study. Bajko, Matthew S. // Bay Area Reporter;11/12/2009, Vol. 39 Issue 46, p1 

    The article reports on the clinical trial of the triple combination antiviral drug therapy (TCAD) to be made by the Quest Clinical Studies, the Covenant Medical Group, and Adamas Pharmaceuticals and will be participated by the people with human immunodeficiency virus (HIV) who contract influenza.

  • New Hope with CD4. Helquist, Michael // Advocate;10/11/88, Issue 509, p22 

    Discusses the potential of anti-AIDS drug, CD4. Clinical trials of CD4.

  • Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. Ghalaut, Veena S; Sangwan, Lata; Dahiya, Kiran; Ghalaut, PS; Dhankhar, Rakesh; Saharan, Rakesh // Journal of Oncology Pharmacy Practice;Jun2012, Vol. 18 Issue 2, p186 

    Nitric oxide (NO) is involved in different stages of malignancies. Increased levels of NO have been reported in different leukemias. Imatinib is the preferred drug for the treatment of chronic myeloid leukemia (CML). Turmeric powder contains curcumin which has anti-leukemic property and also...

  • In vitro Anti-HIV Potency of Stampidine Alone and in Combination with Standard Anti-HIV Drugs. Uckun, Fatih M.; Qazi, Sanjive; Venkatachalam, T. K. // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Apr2005, Vol. 55 Issue 4, p223 

    The purpose of the present study was to compare the in vitro anti-HIV potency of stampidine (CAS 217178-62-6), a novel aryl phosphate derivative of stavudine (CAS 3056-17-5), and drug combinations containing stampidine to the anti-HIV potency of the standard drugs zidovudine (CAS 30516-87-1),...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics